• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nevro Corp.

    8/6/24 4:48:59 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care
    Get the next $NVRO alert in real time by email
    S-8 1 d877780ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 6, 2024

    Registration No. 333-    

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    NEVRO CORP.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   56-2568057

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

    1800 Bridge Parkway

    Redwood City, CA 94065

    (Address of Principal Executive Offices) (Zip Code)

    2023 Employment Inducement Award Plan

    (Full title of the plan)

     

     

    Kevin Thornal

    Chief Executive Officer

    Nevro Corp.

    1800 Bridge Parkway

    Redwood City, CA 94065

    (Name and address of agent for service)

    (650) 251-0005

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Phillip S. Stoup, Esq.

    Latham & Watkins LLP

    505 Montgomery Street, Suite 2000

    San Francisco, CA 94111

    (415) 391-0600

     

    Kashif Rashid, Esq.

    Senior Vice President of Corporate

    Development and Chief Legal Officer

    Nevro Corp.

    1800 Bridge Parkway

    Redwood City, CA 94065

    (650) 251-0005

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 500,000 shares of the Nevro Corp.’s (the “Registrant”) common stock, par value $0.001 per share, issuable under the 2023 Employment Inducement Award Plan for which the Registration Statement of the Registrant on Form S-8 (File No. 333-271390) is effective.

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON

    FORM S-8

    Pursuant to Instruction E of Form S-8, the contents of the Registration Statement on Form S-8 filed with the Securities and Exchange Commission (File Nos. 333-271390) is incorporated by reference herein.

    EXHIBIT INDEX

     

    Exhibit

    Number

     

    Description of Document

       Incorporated by Reference    Filed
    Herewith
       Form    Date    Number
    4.1   Amended and Restated Certificate of Incorporation.    8-K    11/12/2014    3.1   
    4.1(b)   Certificate of Amendment to Amended and Restated Certificate of Incorporation of Nevro Corp.    8-K    5/24/2019    3.1   
    4.2   Amended and Restated Bylaws.    8-K    11/12/2014    3.2   
    4.2(b)   Amendment to Amended and Restated Bylaws of Nevro Corp.    8-K    5/24/2019    3.2   
    4.3   Form of Common Stock Certificate.    S-1/A    10/27/2014    4.2   
    5.1   Opinion of Latham & Watkins LLP.             X
    23.1   Consent of Independent Registered Public Accounting Firm.             X
    23.2   Consent of Latham & Watkins LLP (included in Exhibit 5.1).             X
    24.1   Power of Attorney. Reference is made to the signature page to the Registration Statement.             X
    99.1#   Nevro Corp. 2023 Employment Inducement Award Plan    S-8    4/21/2023    99.1   
    107.1   Filing Fee Table.             X

     

    #

    Indicates management contract or compensatory plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on this 6th day of August, 2024.

     

    NEVRO CORP.
    By:  

    KEVIN THORNAL

    Name:   Kevin Thornal
    Title:   Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Kevin Thornal and Roderick H. MacLeod, and each of them, as attorneys-in-fact, each with the power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

      

    Date

    /s/ KEVIN THORNAL

      

    President and Chief Executive Officer

    (Principal Executive Officer)

       August 6, 2024
    Kevin Thornal   

    /s/ RODERICK H. MACLEOD

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

       August 6, 2024
    Roderick H. MacLeod   

    /s/ D. KEITH GROSSMAN

       Non-Executive Chair    August 6, 2024
    D. Keith Grossman

    /s/ MICHAEL DEMANE

       Lead Director    August 6, 2024
    Michael DeMane      

    /s/ KIRT P. KARROS

       Director    August 6, 2024
    Kirt P. Karros      

    /s/ SRI KOSARAJU

       Director    August 6, 2024
    Sri Kosaraju      

    /s/ SHAWN T MCCORMICK

       Director    August 6, 2024
    Shawn T McCormick      

    /s/ KEVIN O’BOYLE

       Director    August 6, 2024
    Kevin O’Boyle      

    /s/ KAREN PRANGE

       Director    August 6, 2024
    Karen Prange

    /s/ SUSAN E. SIEGEL

       Director    August 6, 2024
    Susan E. Siegel

    /s/ ELIZABETH WEATHERMAN

       Director    August 6, 2024
    Elizabeth Weatherman      
    Get the next $NVRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVRO

    DatePrice TargetRatingAnalyst
    2/10/2025$4.50 → $5.85Underperform → Hold
    Jefferies
    2/7/2025$6.00 → $5.85Neutral → Overweight
    Piper Sandler
    12/3/2024$5.00Equal Weight
    Wells Fargo
    12/2/2024$9.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    8/9/2024Sell → Neutral
    Citigroup
    8/8/2024Underperform → Peer Perform
    Wolfe Research
    8/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024Neutral → Underweight
    JP Morgan
    More analyst ratings

    $NVRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

    REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

    3/4/25 4:15:00 PM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

    AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

    2/6/25 9:30:21 AM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

    REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme

    1/21/25 4:30:00 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NEVRO CORP (0001444380) (Issuer)

    4/3/25 4:30:33 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NEVRO CORP (0001444380) (Issuer)

    4/3/25 4:30:35 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NEVRO CORP (0001444380) (Issuer)

    4/3/25 4:30:38 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    SEC Filings

    View All

    SEC Form 15-12G filed by Nevro Corp.

    15-12G - NEVRO CORP (0001444380) (Filer)

    4/14/25 8:30:09 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Nevro Corp.

    EFFECT - NEVRO CORP (0001444380) (Filer)

    4/8/25 12:15:06 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.

    SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)

    4/4/25 3:49:25 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nevro upgraded by Jefferies with a new price target

    Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously

    2/10/25 7:02:54 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously

    2/7/25 8:27:53 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Wells Fargo initiated coverage on Nevro with a new price target

    Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00

    12/3/24 7:38:11 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Financials

    Live finance-specific insights

    View All

    Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

    REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

    3/4/25 4:15:00 PM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

    AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

    2/6/25 9:30:21 AM ET
    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Reports Third-Quarter 2024 Financial Results

    Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma

    11/11/24 4:05:00 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nevro Corp.

    SC 13G - NEVRO CORP (0001444380) (Subject)

    12/4/24 4:27:18 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Nevro Corp.

    SC 13D/A - NEVRO CORP (0001444380) (Subject)

    11/14/24 5:31:36 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nevro Corp.

    SC 13G/A - NEVRO CORP (0001444380) (Subject)

    11/14/24 5:18:25 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $NVRO
    Leadership Updates

    Live Leadership Updates

    View All

    Nevro Enters Into Cooperation Agreement With Engaged Capital

    Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi

    2/21/24 4:06:00 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Appoints Jon R. Shear as Vice President, Corporate Development

    REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately.   "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and

    4/19/21 7:00:00 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

    REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately.   "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a

    11/30/20 7:00:00 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care